Analysts forecast that Motus GI Holdings Inc (NASDAQ:MOTS) will post sales of $80,000.00 for the current quarter, Zacks reports. Two analysts have provided estimates for Motus GI’s earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $50,000.00. The firm is expected to report its next quarterly earnings report on Wednesday, November 13th.
According to Zacks, analysts expect that Motus GI will report full year sales of $710,000.00 for the current year, with estimates ranging from $410,000.00 to $1.00 million. For the next financial year, analysts forecast that the firm will post sales of $13.84 million, with estimates ranging from $11.07 million to $16.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Motus GI.
Motus GI (NASDAQ:MOTS) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.03.
MOTS has been the topic of a number of recent research reports. Dougherty & Co set a $7.00 target price on Motus GI and gave the company a “buy” rating in a research note on Thursday, September 26th. Zacks Investment Research lowered Motus GI from a “buy” rating to a “hold” rating in a research note on Thursday, August 15th. Finally, ValuEngine raised Motus GI from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd.
Several institutional investors have recently modified their holdings of MOTS. Perceptive Advisors LLC lifted its stake in shares of Motus GI by 31.1% during the 2nd quarter. Perceptive Advisors LLC now owns 4,210,542 shares of the company’s stock worth $12,757,000 after purchasing an additional 1,000,000 shares during the period. Oracle Investment Management Inc. lifted its stake in shares of Motus GI by 35.7% during the 2nd quarter. Oracle Investment Management Inc. now owns 3,766,666 shares of the company’s stock worth $11,413,000 after purchasing an additional 991,666 shares during the period. Maven Securities LTD purchased a new position in shares of Motus GI during the 2nd quarter worth $1,037,000. Granite Point Capital Management L.P. purchased a new position in shares of Motus GI during the 2nd quarter worth $1,010,000. Finally, Vanguard Group Inc. purchased a new position in shares of Motus GI during the 2nd quarter worth $789,000. 44.96% of the stock is currently owned by institutional investors.
Shares of NASDAQ:MOTS traded up $0.07 during trading on Friday, hitting $1.78. 72,709 shares of the stock were exchanged, compared to its average volume of 95,537. Motus GI has a 12-month low of $1.67 and a 12-month high of $4.99. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.92 and a quick ratio of 3.89. The company has a fifty day moving average price of $2.37 and a two-hundred day moving average price of $3.15.
Motus GI Company Profile
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Featured Story: Trading Options- What is a Strangle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.